Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Blood Rev. 2021 Mar 16;49:100825. doi: 10.1016/j.blre.2021.100825

Table 2.

Summary of phase 3 trials comparing second generation tyrosine kinase inhibitors to imatinib as first line therapy for chronic phase CML.

Trial Name Reference Second Generation TKI/Dose Progression Free Survival Overall Survival CCyR (12 months) MMR (12 months)
ENESTnd Hochhaus A et al (79) Nilotinib 300 mg twice daily 5 years: 96.5% 5 years: 93.7% 93%* 44%*
Nilotinib 400 mg twice daily 5 years: 98.3%* 5 years: 96.2%* 93%* 43%*
Imatinib 400 mg once daily 5 years: 94.7% 5 years: 91.7% 76% 22%
BELA Brummendorf TH et al (83) Bosutinib 500 mg once daily 24 months: 92% 24 months: 97% 70% 41%*
Imatinib 400 mg once daily 24 months: 88% 24 months: 95% 68% 27%
BFORE Cortes et al (85) Bosutinib 500 mg once daily 12 months: 96.3 12 months: 99.6% 77.2%* 47.2%*
Imatinib 400 mg once daily 12 months: 93.6 12 months: 97.9% 66.4% 36.9%
DASISION Cortes et al (163) Dasatinib 100 mg once daily 5 year: 85% 5 year: 91% 77%* 46%*
Imatinib 400 mg once daily 5 year: 86% 5 year: 910% 66% 28%

CCyR - complete cytogenetic response; MMR - major molecular response.

*

p<0.05 compared to imatinib.